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Abstract
Background: Alpha-fetoprotein (AFP)-producing gastric cancer is known to frequently cause
multiple liver metastases and to have an extremely poor prognosis.
Case presentation: A 64-year-old Japanese man admitted to our hospital was diagnosed with
gastric cancer with liver metastases. He underwent a total gastrectomy with splenectomy, and
pathological stage IV disease according to the classification proposed by the Japanese Gastric
Cancer Association was assigned. The histological diagnosis was poorly differentiated
adenocarcinoma, and tumor production of AFP was confirmed by immunohistochemical staining.
Following surgery, the patient received combination chemotherapy consisting of TS-1 and
paclitaxel. Initially, AFP levels decreased dramatically and computed tomography (CT) revealed
regression of liver metastases. However, multiple new liver metastases appeared and serum AFP
levels increased after 5 months. A regimen of 5-FU plus paclitaxel followed by paclitaxel
monotherapy was used next. Serum AFP levels once again decreased and CT showed regression
or disappearance of liver metastases. The patient currently has a very good quality of life, and is
receiving weekly paclitaxel monotherapy as an outpatient. No progression of liver metastases has
been observed to date.
Conclusion: We consider this rare case to have significant value with respect to treatment of
AFP-producing gastric cancer with multiple liver metastases, and propose that combining surgery
with chemotherapeutic agents such as paclitaxel may lead to a better prognosis in such cases.
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Alpha-fetoprotein (AFP), which was initially identified
from human fetal tissue, is normally produced in the fetal
liver and yolk sac [1]. Since Bourreille et al., first reported
a patient with gastric tumors that produced AFP, a consid-
erable number of such patients have been identified [2].
AFP-producing gastric cancer is known to frequently cause
multiple liver metastases and to have an extremely poor
prognosis [3-6]. It has been reported that AFP-producing
gastric cancer has high proliferative activity, weak apop-
totic activity, and rich neovascularization compared with
AFP-negative gastric cancer [4]. It is likely that these bio-
logical observations reflect the aggressive clinical behavior
of AFP-producing gastric cancers.
There is no standard chemotherapy available for this dis-
ease, although the following regimens have demonstrated
efficacy in a small number of cases: EAP (etoposide [ETP],
adriamycin, and cisplatin [CDDP]), FAP (5-fluorouracil
[5-FU], epirubicin [EPI], and CDDP), and FAP (5-FU,
adriamycin, and CDDP) [7-9]. The therapeutic efficacy of
irinotecan hydrochloride (CPT-11) and paclitaxel [10,11]
in this disease state has also been recently reported.
In this report, we describe a case with AFP-producing gas-
tric cancer that responded to combination 5-FU/paclitaxel
chemotherapy followed by a bi-weekly course of paclit-
axel monotherapy.
Case presentation
A 64-year-old Japanese man admitted to Nagoya City Uni-
versity Hospital because of upper abdominal pain was
diagnosed with gastric cancer with liver metastases. His
family history was unremarkable. Laboratory data on
admission revealed liver dysfunction as follows: serum
glutamic oxaloacetic transaminase (SGOT), 125 U/L (nor-
mal range, 10–33 U/L); glutamic pyruvic transferase
(SGPT), 252 U/L (normal range, 6–37 U/L); γ-glutamyl
transpeptidase (γ-GTP), 1435 U/L (normal range, 10–47
U/L); alkaliphosphatase (ALP), 988 U/L (normal range,
115–359 U/L). AFP and carcinoembryonic antigen (CEA)
levels were 1497.8 ng/ml and 72.7 ng/ml, respectively.
Abdominal computed tomography (CT) showed
enhanced thickness of the gastric wall and multiple liver
metastases (Figure 1A). Gastroscopy revealed a Borrmann
type III tumor on the lesser curvature in the midportion of
the stomach (Figure 1B), which was diagnosed as gastric
carcinoma upon histological examination of a biopsy
specimen. After informed consent with enough detailed
explanation about the patient's disease, he wished a surgi-
cal treatment strongly. The patient underwent surgical
resection (total gastrectomy with splenectomy). The path-
ological stage was IV: T3, N1, H1, P0 according to the clas-
sification proposed by the Japanese Gastric Cancer
Association [12], and the histological diagnosis was
poorly differentiated adenocarcinoma. Lymphatic inva-
sion was moderate and venous invasion was negative.
Tumor production of AFP was confirmed by immunohis-
tochemical staining (Figure 2A and 2B).
(A) Abdominal computed tomography (CT) revealed enhanced thickness of the gastric wall and multiple liver metastasesFigure 1
(A) Abdominal computed tomography (CT) revealed enhanced thickness of the gastric wall and multiple liver metastases. (B) 
Gastroscopy revealed a Borrmann type III tumor on the lesser curvature in the midportion of the stomach.Page 2 of 5
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mg on days 1 and 8) and TS-1 (100 mg/day for 2 weeks
and discontinuation for 1 week) after surgery. After 3
months, the level of AFP had remarkably decreased from
4344.0 ng/ml to 418.9 ng/ml. After 4 months, CT revealed
regression of liver metastases (Figure 3A). However, after
5 months, multiple new liver metastases were apparent
(Figure 3B) and serum AFP had increased to 8189.0 ng/
ml. Furthermore, an ileus occurred due to peritonitis car-
cinomatous. We therefore tried a regimen of 5-FU (500
mg/day via continuous infusion for 7 days) plus paclitaxel
(120 mg weekly) at weekly intervals. After one treatment
course, 5-FU administration was stopped but paclitaxel
(120 mg) monotherapy was continued for 6 weeks. Serum
AFP levels decreased again (to 709.7 ng/ml) and CT
revealed that the liver metastases had either regressed or
disappeared (Figure 3C). The patient currently has a very
good quality of life, and is receiving weekly paclitaxel
monotherapy as an outpatient. Three months have passed
since 5-FU/paclitaxel treatment was started; no progres-
sion of liver metastases has been observed to date.
Discussion
AFP-producing gastric cancers should be divided in to
three subtypes: 1) hepatoid type; 2) yolk sac tumor-like
type; and 3) fetal gastrointestinal type [13]. The hepatoid
type was the most common one of AFP-producing gastric
cancer, and they were described as hepatoid adenocarci-
noma that means primary gastric cancer that are character-
ized by both hepatoid differentiation and the production
of AFP [14,15]. Our case had the tumor that was classified
as having a hepatoid subtype. Unfortunately, most
hepatoid type tumor tends to be highly malignant [13].
AFP-producing gastric cancer has a high proliferative
activity, weak apoptosis, and rich neovascularization [4].
Recent reports described that some factors associated with
mitosis, cell movement, proliferative activity, and tumor
progression such as Ki-67, hepatocyte growth factor
(HGF) and its receptor, c-Met, vascular endothelial
(A) Enhanced CT revealed that liver metastases had decreased in size following initial therapyFigure 3
(A) Enhanced CT revealed that liver metastases had decreased in size following initial therapy. (B) After 5 months of treat-
ment, multiple liver metastases reappeared in segments 1, 3, and 5. (C) Following second-line treatment with 5-FU/paclitaxel 
and paclitaxel monotherapy, liver metastases either regressed or disappeared.
Resected specimen of stomach was fixed with 10% formalin and embedded in paraffinFigure 2
Resected specimen of stomach was fixed with 10% formalin and embedded in paraffin. Sections were stained with (A) hema-
toxylin-eosin staining (× 200) , (B) alpha-fetoprotein (× 200), or (C) negative control IgG (× 200).Page 3 of 5
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to be highly expressed in AFP-producing gastric cancer
and might contribute to the poor prognosis and drug
resistance of this tumor [4,16,17].
Few successful treatment options exist for AFP-producing
gastric cancer. While surgical resection is considered to be
somewhat effective, approximately 50% of patients who
undergo curative resection of the primary tumor eventu-
ally die due to recurrence, most of them with multiple
liver metastases [18]. Indeed, AFP-producing gastric can-
cer is associated with a high incidence of multiple liver
metastases, which render resection impossible. Moreover,
AFP-producing gastric cancer is reported to respond
poorly to a number of chemotherapy regimens. The use of
various chemotherapeutic protocols that are active in
other types of cancer have been reported, although their
efficacy in gastric cancer is controversial [7-11]. Some
investigators have reported that AFP-producing gastric
cancer can be treated successfully with preoperative (i.e.,
neoadjuvant) combination chemotherapy with EPI, 5-FU,
and leucovorin (LV) [19]. Kochi et al., have also reported
the use of a combination chemotherapy regimen consist-
ing of 5-FU, LV, ETP, and CDDP (designated as the FLEP
regimen) for inoperable stage IV gastric cancer [20,21].
FLEP chemotherapy was more effective for stage IV AFP-
producing gastric cancer than for stage IV non-AFP-pro-
ducing gastric cancer, and it improved the prognosis of
AFP-producing gastric cancer due to downstaging.
TS-1 has shown superior results in the treatment of gastric
cancer both as monotherapy and in combination with
other agents. In a phase II clinical trial in Japan, single
administration of TS-1 yielded a higher response rate
(46.5%, 60/129 cases), longer median survival time
(MST; 8.1 months), and lower incidence of adverse events
compared to historical controls (e.g., 5-FU, methotrexate
+ LV, CDDP). It has proven to be one of the most promis-
ing new anti neoplastic agents [22]. However, in poorly
differentiated gastric cancer, the agents described above
are only effective in a small proportion of patients. Several
case reports have demonstrated the efficacy of TS-1 mon-
otherapy against malignant ascites. The novel antimitotic
agent paclitaxel inhibits cell division by promoting tubu-
lin polymerization and stabilizing microtubules [23]. This
agent has been used as second-line treatment in patients
with gastric cancer, particularly for cases refractory to first-
line drugs (i.e., CDDP, 5-FU) or who experience recur-
rence following surgery.
As monotherapy, paclitaxel has been shown to result in a
response rate of 26% in gastric cancer patients with previ-
ously treated by surgery and 21% in those with prior
chemotherapy. Remarkably, paclitaxel is the only mono-
therapy shown to increase MST to longer than 300 days in
patients with advanced and recurrent gastric cancer,
regardless of prior treatment history [24]. Recently, some
cases responding to paclitaxel treatment were reported.
Chiba et al., reported the case of AFP-producing hepatoid
adenocarcinoma in association with Barrett's esophagus
with multiple liver metastases responding to paclitaxel/
CDDP [25]. Hirashima et al., reported the successful bi-
weekly paclitaxel treatment of an AFP-producing gastric
cancer [11], however, there was no English literature
which described the efficacy of paclitaxel for AFP-produc-
ing gastric cancers.
In our patient, we first used TS-1 and paclitaxel combina-
tion chemotherapy. Initially, the patient's AFP levels dra-
matically decreased and CT showed regression of
metastatic liver tumors; however, multiple new liver
metastases appeared and serum AFP levels increased after
5 months. Furthermore, the patient suffered an ileus due
to peritonitis carcinomatous. Consequentially, we used
combination 5-FU and paclitaxel chemotherapy with sub-
sequent paclitaxel monotherapy as second-line treatment.
This regimen resulted in the disappearance or reduction in
size of many liver metastases, and greatly improved the
patient's quality of life. The most significant toxicity, leu-
kopenia, was effectively controlled with granulocyte col-
ony-stimulating factors.
Conclusion
To our knowledge, this is the first case report in the Eng-
lish literature of an AFP-producing gastric cancer associ-
ated with multiple liver metastases that was successfully
treated with paclitaxel. We consider this rare case to be of
significant value with respect to the treatment of AFP-pro-
ducing gastric cancer with multiple liver metastases. We
feel that combining surgery with chemotherapy such as
paclitaxel will lead to a better prognosis in such cases. We
also believe that our protocol is an effective and safe treat-
ment for liver metastases associated with AFP-producing
gastric cancer. Nevertheless, further clinical evaluation of
this regimen in advanced AFP-producing gastric cancer
with liver metastases is required.
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